Bharat Biotech said iNCOVACC is world’s first intranasal vaccine to get approval from Central Drugs Standard Control Organisation for use as heterologous booster doses in India.
A press release from Corbevax maker said it could be administered as a booster after six months of administration of primary vaccination for restricted use in emergency situation.
Non-peer-reviewed study by Hyderabad’s AIG Hospitals & Asian Health Foundation focuses on these 30%. AIG head says 70% who retain antibodies can benefit from booster after 9 months.
Vaccine hesitancy and surging infections among healthcare workers believed to be likely reasons for fall in booster demand. Numbers fluctuating for frontline workers & senior citizens.
With senior citizens and frontline workers getting the third dose of vaccines, ThePrint explains when they are needed, and what booster shots do to bolster the immune system.
New Delhi: During Operation Sindoor, the United States which had received intelligence suggesting that India had launched BrahMos cruise missiles to strike targets inside...
COMMENTS